Evidence map›Paper›PMID 18517036›Full record

Trial reportSleep2008

Slow wave sleep enhancement with gaboxadol reduces daytime sleepiness during sleep restriction.

James K Walsh, Ellen Snyder, Janine Hall, Angela C Randazzo, Kara Griffin, John Groeger, Rhody Eisenstein, Stephen D Feren, Pam Dickey, Paula K Schweitzer

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Sleep, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 56 citations in OpenAlex.

  1. EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2011
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

James K WalshSleep Medicine & Research Center, St. John's Mercy Medical Center/St. Luke's Hospital, St. Louis, MO, USA. walsjk@stlo.smhs.com
Ellen Snyder
Janine Hall
Angela C Randazzo
Kara Griffin
John Groeger
Rhody Eisenstein
Stephen D Feren
Pam Dickey
Paula K Schweitzer
St. Luke's Hospital · USMercy Medical Center · USSt. Vincent's Medical Center · USUniversity of Surrey · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesTo evaluate the impact of enhanced slow wave sleep (SWS) on behavioral, psychological, and physiological changes resulting from sleep restriction.

designA double-blind, parallel group, placebo-controlled design was used to compare gaboxadol (GBX) 15 mg, a SWS-enhancing drug, to placebo during 4 nights of sleep restriction (5 h/night). Behavioral, psychological, and physiological measures of the impact of sleep restriction were assessed in both groups at baseline, during sleep restriction and following recovery sleep.

settingSleep research laboratory.

participantsForty-one healthy adults; 9 males and 12 females (mean age: 32.0 +/- 9.9 y) in the placebo group and 10 males and 10 females (mean age: 31.9 +/- 10.2 y) in the GBX group.

interventionsBoth experimental groups underwent 4 nights of sleep restriction. Each group received either GBX 15 mg or placebo on all sleep restriction nights, and both groups received placebo on baseline and recovery nights. MEASUREMENTS AND

resultsPolysomnography documented a SWS-enhancing effect of GBX with no group difference in total sleep time during sleep restriction. The placebo group displayed the predicted deficits due to sleep restriction on the multiple sleep latency test (MSLT) and on introspective measures of sleepiness and fatigue. Compared to placebo, the GBX group showed significantly less physiological sleepiness on the MSLT and lower levels of introspective sleepiness and fatigue during sleep restriction. There were no differences between groups on the psychomotor vigilance task (PVT) and a cognitive test battery, but these measures were minimally affected by sleep restriction in this study. The correlation between change from baseline in MSLT on Day 6 and change from baseline in SWS on Night 6 was significant in the GBX group and in both group combined.

conclusionsThe results of this study are consistent with the hypothesis that enhanced SWS, in this study produced by GBX, reduces physiological sleep tendency and introspective sleepiness and fatigue which typically result from sleep restriction.

Indexed as

AdultAffectArousalAttentionCircadian RhythmDisorders of Excessive SomnolenceDouble-Blind MethodElectroencephalographyEpinephrineFatigueFemaleFourier AnalysisGABA AgonistsHumansHydrocortisoneIsoxazolesEpinephrineGABA AgonistsgaboxadolHydrocortisoneIsoxazolesNorepinephrine

Identifiers

PMID18517036
PMCPMC2398757
OpenAlexW2140211350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.